Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database

• Главные авторы: Junwei Wang (Автор), Aiwei Zhang (Автор), Miaoyong Ye (Автор), Cunming Zhang (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: Mirabegron, the first β-3 adrenergic receptor agonist, received approval from the Food and Drug Administration (FDA) in 2012 for the treatment of overactive bladder (OAB). This pharmacovigilance study investigated the safety profile of mirabegron treatment using the US FDA Adverse Event...